|Trade names||Pepcid, others|
|By mouth (tablets), Intravenous|
|Bioavailability||40–45% (by mouth)|
|Elimination half-life||2.5–3.5 hours|
|Excretion||Kidney (25–30% unchanged [Oral])|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||337.44 g·mol−1|
|3D model (JSmol)|
Famotidine, sold under the brand name Pepcid among others, is a medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.
Common side effects include headache, intestinal upset, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied while use during breastfeeding is not recommended. It is a histamine H2 receptor antagonist.
Famotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. A month supply in the United Kingdom costs the NHS about £30 as of 2019. In the United States the wholesale cost of this amount is about $2. In 2017, it was the 115th most commonly prescribed medication in the United States, with more than six million prescriptions.
- Relief of heartburn, acid indigestion, and sour stomach
- Treatment for gastric and duodenal ulcers
- Treatment for pathologic gastrointestinal hypersecretory conditions such as Zollinger–Ellison syndrome and multiple endocrine adenomas
- Treatment for gastroesophageal reflux disease (GERD)
- Treatment for esophagitis
- Part of a multidrug regimen for Helicobacter pylori eradication, although omeprazole may be somewhat more effective.
- Prevention of NSAID-induced peptic ulcers.
- Given to surgery patients before operations to reduce the risk of aspiration pneumonitis.
Mechanism of action
Activation of H2 receptors located on parietal cells stimulates proton pumps to secrete acid into the stomach lumen. Famotidine, an H2 antagonist, blocks the action of histamine on the parietal cells, ultimately reducing acid secretion into the stomach.
Famotidine was developed by Yamanouchi Pharmaceutical Co. It was licensed in the mid-1980s by Merck & Co. and is marketed by a joint venture between Merck and Johnson & Johnson. The imidazole ring of cimetidine was replaced with a 2-guanidinothiazole ring. Famotidine proved to be nine times more potent than ranitidine, and thirty-two times more potent than cimetidine.
In the United States and Canada, a product called Pepcid Complete, which combines famotidine with an antacid in a chewable tablet to quickly relieve the symptoms of excess stomach acid, is available. In the UK, this product was known as Pepcidtwo prior to its discontinuation in April 2015.
Famotidine has poor bioavailibility (50%) due to low gastroretention time. Famotidine is less soluble at higher pH, and when used in combination with antacids gastroretention time is increased. This promotes local delivery of these drugs to receptors in the parietal cell wall and increases bioavailibility. Researchers are developing tablet formulations that rely on other gastroretentive drug delivery systems such as floating tablets to further increase bioavailibility.
Certain preparations of famotidine are available over the counter (OTC) in various countries. In the United States and Canada, 10 mg and 20 mg tablets, sometimes in combination with an antacid, are available OTC. Larger doses still require a medical prescription.
- Truven Health Analytics, Inc. DRUGDEX® System (Internet) [cited 2013 Oct 10]. Greenwood Village, CO: Thomsen Healthcare; 2013.
- "Famotidine Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
- British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 74–75. ISBN 9780857113382.
- "Famotidine Use During Pregnancy". Drugs.com. Retrieved 3 March 2019.
- Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 444. ISBN 9783527607495.
- "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
- "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
- "Famotidine - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
- Kanayama S (January 1999). "[Proton-pump inhibitors versus H2-receptor antagonists in triple therapy for Helicobacter pylori eradication]". Nihon Rinsho. Japanese Journal of Clinical Medicine. 57 (1): 153–6. PMID 10036954.
- Soga T, Matsuura M, Kodama Y, Fujita T, Sekimoto I, Nishimura K, et al. (August 1999). "Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis?". Journal of Gastroenterology. 34 (4): 435–40. doi:10.1007/s005350050292. PMID 10452673.
- Borody TJ, Andrews P, Fracchia G, Brandl S, Shortis NP, Bae H (October 1995). "Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori". Gut. 37 (4): 477–81. doi:10.1136/gut.37.4.477. PMC 1382896. PMID 7489931.
- Hu FL, Jia JC, Li YL, Yang GB (2003). "Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer". The Journal of International Medical Research. 31 (6): 469–74. doi:10.1177/147323000303100601. PMID 14708410.
- Kirika NV, Bodrug NI, Butorov IV, Butorov SI (2004). "[Efficacy of different schemes of anti-helicobacter therapy in duodenal ulcer]". Terapevticheskii Arkhiv. 76 (2): 18–22. PMID 15106408.
- Fujiwara Y, Higuchi K, Nebiki H, Chono S, Uno H, Kitada K, et al. (June 2005). "Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease". Alimentary Pharmacology & Therapeutics. 21 (Suppl 2): 10–8. doi:10.1111/j.1365-2036.2005.02468.x. PMID 15943841.
- La Corte R, Caselli M, Castellino G, Bajocchi G, Trotta F (June 1999). "Prophylaxis and treatment of NSAID-induced gastroduodenal disorders". Drug Safety. 20 (6): 527–43. doi:10.2165/00002018-199920060-00006. PMID 10392669.
- Laine L, Kivitz AJ, Bello AE, Grahn AY, Schiff MH, Taha AS (March 2012). "Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers". The American Journal of Gastroenterology. 107 (3): 379–86. doi:10.1038/ajg.2011.443. PMC 3321505. PMID 22186979.
- Escolano F, Castaño J, López R, Bisbe E, Alcón A (October 1992). "Effects of omeprazole, ranitidine, famotidine and placebo on gastric secretion in patients undergoing elective surgery". British Journal of Anaesthesia. 69 (4): 404–6. doi:10.1093/bja/69.4.404. PMID 1419452.
- Vila P, Vallès J, Canet J, Melero A, Vidal F (November 1991). "Acid aspiration prophylaxis in morbidly obese patients: famotidine vs. ranitidine". Anaesthesia. 46 (11): 967–9. doi:10.1111/j.1365-2044.1991.tb09860.x. PMID 1750602.
- Jahr JS, Burckart G, Smith SS, Shapiro J, Cook DR (July 1991). "Effects of famotidine on gastric pH and residual volume in pediatric surgery". Acta Anaesthesiologica Scandinavica. 35 (5): 457–60. doi:10.1111/j.1399-6576.1991.tb03328.x. PMID 1887750.
- "Famotidine". PetMD.
- Fogg TB, Semple D (29 November 2007). "Combination therapy with H2 and H1 antihistamines in acute, non compromising allergic reactions". BestBets. Manchester, England: Manchester Royal Infirmary. Retrieved 26 April 2011.
- "Common Side Effects of Pepcid (Famotidine) Drug Center". RxList. Retrieved 2019-03-02.
- "Drugs & Medications". www.webmd.com. Retrieved 2019-03-02.
- Fazio G, Vernuccio F, Grutta G, Re GL (26 April 2013). "Drugs to be avoided in patients with long QT syndrome: Focus on the anaesthesiological management". World Journal of Cardiology. 5 (4): 87–93. doi:10.4330/wjc.v5.i4.87. PMC 3653016. PMID 23675554.
- Lee KW, Kayser SR, Hongo RH, Tseng ZH, Scheinman MM (May 2004). "Famotidine and long QT syndrome". The American Journal of Cardiology. 93 (10): 1325–1327. doi:10.1016/j.amjcard.2004.02.025. PMID 15135720.
- Humphries TJ, Merritt GJ (August 1999). "Review article: drug interactions with agents used to treat acid-related diseases". Alimentary Pharmacology & Therapeutics. 13 (Suppl 3): 18–26. doi:10.1046/j.1365-2036.1999.00021.x. PMID 10491725.
- US patent 4283408, Yasufumi Hirata, Isao Yanagisawa, Yoshio Ishii, Shinichi Tsukamoto, Noriki Ito, Yasuo Isomura and Masaaki Takeda, "Guanidinothiazole compounds, process for preparation and gastric inhibiting compositions containing them", issued 11 August 1981
- "Sankyo Pharma". Skyscape Mediwire. 2002. Archived from the original on 23 February 2009. Retrieved 31 October 2009.
- Howard JM, Chremos AN, Collen MJ, McArthur KE, Cherner JA, Maton PN, et al. (April 1985). "Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome". Gastroenterology. 88 (4): 1026–33. doi:10.1016/s0016-5085(85)80024-x. PMID 2857672.
- "PepcidTwo Chewable Tablet". Archived from the original on 18 July 2016. Retrieved 7 June 2015.
- "Formulation and Evaluation of Gastroretentive Floating Tablets of Famotidine". Farmavita.Net. 2008. Archived from the original on 29 March 2016. Retrieved 31 January 2009.
- Pepcid Complete
- "Famotidine". Medline Plus.
- "Duexis". Drugs.com.
|Wikimedia Commons has media related to Famotidine.|
- "Famotidine". Drug Information Portal. U.S. National Library of Medicine.